The Future of Branded and Generic Drugs

'Patentbusters: The Uncertain Future of Branded and Generic Drugs in the Wake of Plavix and Apotex' An Audio Conference from F-D-C Reports

Join F-D-C Reports on Thursday, Oct. 12, 2006 to get the most up-to-date review and analysis of this latest patent dispute. In one concise 90-minute audio conference—which one can attend from the comfort of an office or home —learn why this case is so critical to brand and generic drug manufacturers alike.

Rockville, MD -- Executives from a brand or generic company, lawyers, biopharmaceutical consultants, regulatory affairs representatives and financial analysts should not miss this chance to hear and speak with a panel of experts as they explore this patent dispute from a business, legal and regulatory perspective. Get an inside look, straight from former executives at the FTC, FDA and USPTO.

Speakers are:
* David Balto, Executive VP and COO, Robins, Kaplan, Miller & Ciresi (former Policy Director, Bureau of Competition, U.S. Federal Trade Commission);
* Robert Dormer, Partner Hyman, Phelps & MacNamara (former Associate Chief Counsel for Enforcement and Associate Chief Counsel for Radiological Health, U.S. Food & Drug Administration);
* James Wallace, Partner, Wiley Rein & Fielding (litigator in BlackBerry patent case and former U.S. Department of Justice trial attorney and U.S. Patent & Trademark examiner); and
* Joshua Berlin, Executive Editor, "The Pink Sheet" DAILY.

To learn more about the potential fallout from this latest battle, join F-D-C Reports on Thursday, October 12, 2006, for an audio conference that will explore the potential financial and regulatory implications, and discuss how the outcome could affect companies.

Register today at http://www.fdcreports.com/audio

Brand name drug companies are struggling to protect their patents against increasingly aggressive competition from generic manufacturers. The battle over the rights to Plavix is the most recent example of the ongoing war between brand and generic companies over drug patents.

This audio conference will help professionals:
* Understand the legal, financial and regulatory ramifications of the Plavix/Apotex case for the biopharmaceutical industry
* Get an inside look at the complex patent, trade and brand/generic drug perspectives
* Find out what the fallout from this landmark case is likely to be
* Hear who will be the likely winners and the losers

To register or to find out more, please go to http://www.fdcreports.com/audio

About F-D-C Reports:
F-D-C Reports provides up-to-date information about the worldwide health care industry via its publications including The Pink Sheet(R), The Gray Sheet(R), The Rose Sheet(R), The Tan Sheet(R), and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand developments affecting the US regulation and marketing of healthcare products and services. F-D-C Reports has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the US drug, biotech, medical device, nonprescription drug, nutritionals and cosmetics industries. For more information, please visit: www.fdcreports.com

FDC Reports, Inc. is part of Elsevier. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products and online reference works. For more information, visit: www.elsevier.com

Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (NYSE). For more information, visit: www.reed-elsevier.com.


Press Contact: Eileen Bertrand
Company Name:
Phone: 240-221-4500
Website: